5 hours After Plunging -31.47% in 4 Weeks, Here’s Why the Trend Might Reverse for Prelude Therapeutics (PRLD)Zacks

Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Earnings · Wall Street